加味川芎平喘合剂治疗慢性阻塞性肺疾病稳定期合并肺动脉高压的临床疗效观察
|
摘要
目的:观察加味川芎平喘合剂对慢性阻塞性肺疾病(COPD)稳定期合并肺动脉高压(PH)痰瘀阻肺型患者的临床疗效及其对凝血因子的影响。方法:将80例COPD稳定期合并PH患者随机分为2组:对照组给予西医常规治疗,治疗组在西医常规治疗基础上给予加味川芎平喘合剂,疗程均为12周。观察并记录两组患者治疗前后临床疗效变化、肺动脉压力、凝血等相关检测指标变化情况。结果:治疗组临床疗效显著优于对照组(P<0.05)。治疗后,治疗组咳嗽、喘息、胸闷、气短等中医症状积分显著低于对照组(P<0.05),肺动脉压力较治疗前显著下降(P<0.05);FIB、D-二聚体水平均较治疗前显著下降(P<0.05),且低于同期对照组(P<0.05)。结论:加味川芎平喘合剂可改善COPD稳定期合并PH患者的临床症状,可一定程度降低患者肺动脉压力,并有效降低FIB、D-二聚体水平。
Objective: To observe the clinical effect of modified Chuanxiong Pingchuan Mixture on patients with stable phase of chronic obstructive pulmonary disease(COPD) complicated with pulmonary hypertension(PH) of phlegm and blood stasis resistance lung syndrome and its effect on blood coagulation factors. Methods: Eighty patients with stable phase of COPD who had PH were randomly divided into two groups. The control group was given routine western medicine treatment.The treatment group was given modified Chuanxiong Pingchuan Mixture on the basis of routine western medicine treatment, the course of treatment was 12 weeks. The changes of clinical efficacy, pulmonary artery pressure, coagulation, and other related indicators before and after treatment in the two groups of patients were observed and recorded. Results: The clinical efficacy of the treatment group was better than that of the control group, with significant differences(P<0.05). After treatment, the total scores of symptoms such as cough, wheezing, chest tightness, and shortness of breath in the treatment group were significantly lower than those in the control group(P<0.05), pulmonary arterial pressure in the treatment group was significantly lower than that before treatment(P<0.05); FIB and D-dimer levels were significantly lower than that before treatment(P<0.05). And the levels of FIB and D-dimer in the treatment group were significantly lower than those in the control group(P<0.05). Conclusion: Modified Chuanxiong Pingchuan Mixture can improve the clinical symptoms of stable phase of COPD in patients with PH, and can reduce the pulmonary artery pressure to a certain extent and effectively reduce the levels of FIB and D-dimer.
Objective: To observe the clinical effect of modified Chuanxiong Pingchuan Mixture on patients with stable phase of chronic obstructive pulmonary disease(COPD) complicated with pulmonary hypertension(PH) of phlegm and blood stasis resistance lung syndrome and its effect on blood coagulation factors. Methods: Eighty patients with stable phase of COPD who had PH were randomly divided into two groups. The control group was given routine western medicine treatment.The treatment group was given modified Chuanxiong Pingchuan Mixture on the basis of routine western medicine treatment, the course of treatment was 12 weeks. The changes of clinical efficacy, pulmonary artery pressure, coagulation, and other related indicators before and after treatment in the two groups of patients were observed and recorded. Results: The clinical efficacy of the treatment group was better than that of the control group, with significant differences(P<0.05). After treatment, the total scores of symptoms such as cough, wheezing, chest tightness, and shortness of breath in the treatment group were significantly lower than those in the control group(P<0.05), pulmonary arterial pressure in the treatment group was significantly lower than that before treatment(P<0.05); FIB and D-dimer levels were significantly lower than that before treatment(P<0.05). And the levels of FIB and D-dimer in the treatment group were significantly lower than those in the control group(P<0.05). Conclusion: Modified Chuanxiong Pingchuan Mixture can improve the clinical symptoms of stable phase of COPD in patients with PH, and can reduce the pulmonary artery pressure to a certain extent and effectively reduce the levels of FIB and D-dimer.
引文
[1]王蕾,杨汀,王辰.2017年版慢性阻塞性肺疾病诊断、处理和预防全球策略解读.中国临床医生杂志,2017,45(1):104-108
[2]WHO.Global Health Estimates Summary Tables:Deaths by Cause,Age and Sex by various regional grouping.Geneva:World Health Organization,2013
[3]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):A national cross-sectional study.Lancet,2018,391(10131):1706-1717
[4]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版).中华结核和呼吸杂志,2013,6(4):484-491
[5]中华医学会心血管病学分会.肺动脉高压筛查诊断与治疗专家共识.中华心血管病杂志,2007,35(11):979-987
[6]CFDA.中药新药临床研究指导原则(试行).北京:中国医药科技出版社,2002:54-58
[7]国家技术监督局.中华人民共和国国家标准中医临床诊疗术语:证候部分.北京:中国标准出版社,1997:44
[8]刘轶华,穆晓燕,陈保红.水蛭活血成分研究及临床应用.中国现代药物应用,2013,7(11):192-193
[9]卢奎多,赵艳波.中药水蛭中的微量元素和氨基酸的分析.光明中医,2010,25(6):956-957
[10]王道芳.浅述桃仁与苦杏仁的药理及临床应用.现代中药研究与实践,2002,16(6):61-62
[11]以敏,邓家刚,郝二伟,等.桃仁对血液循环障碍大鼠内皮细胞凋亡及相关蛋白表达的影响.中国实验方剂学杂志,2013,19(14):178-182
[12]郭晓燕,张晔敏,鹿振辉,等.川芎平喘合剂对慢性阻塞性肺疾病急性加重期血栓前状态的影响.辽宁中医杂志,2014,41(4):622-624
[13]Wu Q H.Pharmacology of traditinal Chinese Medicine.Beijing:Higher Education Press,2007:171-173
[14]国家药典委员会.中华人民共和国药典.北京:中国医药科技出版社,2010:287
[15]Oudijk E J,Lammers J W,Koenderman L.Systemic inflammation in chronic obstructive pulmonary disease.Proc Am Thorac Soc,2007,46(Supplement 46):626-634
[2]WHO.Global Health Estimates Summary Tables:Deaths by Cause,Age and Sex by various regional grouping.Geneva:World Health Organization,2013
[3]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):A national cross-sectional study.Lancet,2018,391(10131):1706-1717
[4]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版).中华结核和呼吸杂志,2013,6(4):484-491
[5]中华医学会心血管病学分会.肺动脉高压筛查诊断与治疗专家共识.中华心血管病杂志,2007,35(11):979-987
[6]CFDA.中药新药临床研究指导原则(试行).北京:中国医药科技出版社,2002:54-58
[7]国家技术监督局.中华人民共和国国家标准中医临床诊疗术语:证候部分.北京:中国标准出版社,1997:44
[8]刘轶华,穆晓燕,陈保红.水蛭活血成分研究及临床应用.中国现代药物应用,2013,7(11):192-193
[9]卢奎多,赵艳波.中药水蛭中的微量元素和氨基酸的分析.光明中医,2010,25(6):956-957
[10]王道芳.浅述桃仁与苦杏仁的药理及临床应用.现代中药研究与实践,2002,16(6):61-62
[11]以敏,邓家刚,郝二伟,等.桃仁对血液循环障碍大鼠内皮细胞凋亡及相关蛋白表达的影响.中国实验方剂学杂志,2013,19(14):178-182
[12]郭晓燕,张晔敏,鹿振辉,等.川芎平喘合剂对慢性阻塞性肺疾病急性加重期血栓前状态的影响.辽宁中医杂志,2014,41(4):622-624
[13]Wu Q H.Pharmacology of traditinal Chinese Medicine.Beijing:Higher Education Press,2007:171-173
[14]国家药典委员会.中华人民共和国药典.北京:中国医药科技出版社,2010:287
[15]Oudijk E J,Lammers J W,Koenderman L.Systemic inflammation in chronic obstructive pulmonary disease.Proc Am Thorac Soc,2007,46(Supplement 46):626-634